Proteome profiling to advance management of metabolic dysfunction-associated fatty liver disease  

作　　者：Mohammed Eslam Nahum Méndez-Sánchez Ming-Hua Zheng 

机构地区：[1]Storr Liver Centre,Westmead Institute for Medical Research,Westmead Hospital and University of Sydney,Sydney,NSW,Australia [2]Liver Research Unit,Medica Sur Clinic Foundation,Mexico City,Mexico [3]MAFLD Research Center,Department of Hepatology,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China [4]Institute of Hepatology,Wenzhou Medical University,Wenzhou,China [5]Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province,Wenzhou,China

出　　处：《Hepatobiliary Surgery and Nutrition》2024年第1期147-149,共3页肝胆外科与营养（英文）

基　　金：supported by the National Health and Medical Research Council of Australia(NHMRC)Program and Investigator Grants(Nos.2008983,1053206,and 1149976);Project and Ideas Grants(Nos.1107178,1108422,and 2001692).

摘　　要：Metabolic dysfunction-associated fatty liver disease(MAFLD)is a complex,heterogenous and progressive disease that is characterised by substantial phenotypic variability,which results in disparate clinical presentations and outcomes(1-4).Notably,only a proportion of patients with MAFLD progress to the more advanced stages of the disease.Therefore,the identification of the subgroups that have a high risk of disease progression is of paramount importance for clinical care,as well as drug development and clinical trials(5).

关 键 词：Metabolic dysfunction-associated fatty liver disease(MAFLD) fatty liver disease(FLD) FIBROSIS PROTEOME biomarkers 

分 类 号：R575.5[医药卫生—消化系统]